Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Usage Information

Inhibitory guanosine triphosphate-binding protein-mediated regulation of vasopressin action in isolated single medullary tubules of mouse kidney.
K Takaichi, K Kurokawa
K Takaichi, K Kurokawa
View: Text | PDF
Research Article

Inhibitory guanosine triphosphate-binding protein-mediated regulation of vasopressin action in isolated single medullary tubules of mouse kidney.

  • Text
  • PDF
Abstract

Vasopressin (AVP) plays a key role in maximal urine concentration by stimulating NaCl reabsorption in the medullary thick ascending limbs of Henle (MAL) and by increasing water permeability in the medullary collecting tubules (MCT). These effects of AVP in MAL and MCT are mediated by cAMP. Alpha 2-adrenergic stimulation in MCT, and high ambient Ca2+ and PGE2 in MAL inhibit AVP-dependent cAMP production and thereby modulate urine concentration. The present study was undertaken to clarify the mechanisms underlying the inhibition of AVP-dependent cAMP production by these agents using microdissected mouse MAL and MCT. Preincubation of MCT and MAL with 1 microgram/ml pertussis toxin for 3 and 6 h, respectively, resulted in ADP-ribosylation of an approximately 41-kD protein, which was presumably an alpha subunit of the inhibitory GTP-binding protein Gi. Epinephrine, 10(-6) M, via alpha 2-adrenergic stimulation, inhibited AVP-dependent cAMP production in MCT. Preincubation of MCT for 3 h with pertussis toxin abolished the inhibition of AVP-dependent cAMP production by epinephrine. High ambient Ca2+ and PGE2 both inhibited AVP-dependent cAMP production in MAL. Preincubation of MAL for 6 h with pertussis toxin abolished the inhibition by high ambient Ca2+ and attenuated the inhibition by PGE2. Preincubation of MCT or MAL with pertussis toxin for 1 h was ineffective in ADP-ribosylation and did not modify the inhibition of AVP-dependent cAMP production by these agents in both nephron segments. Our data suggest that the inhibition of AVP-dependent cAMP production by alpha 2-adrenergic stimulation in MCT, and by high ambient Ca2+ and adrenergic stimulation in MCT, and by high ambient Ca2+ and PGE2 in MAL, is mediated, at least in part, through activation of Gi.

Authors

K Takaichi, K Kurokawa

×

Usage data is cumulative from July 2025 through July 2026.

Usage JCI PMC
Text version 267 9
PDF 95 10
Scanned page 505 0
Citation downloads 155 0
Totals 1,022 19
Total Views 1,041
(Click and drag on plot area to zoom in. Click legend items above to toggle)

Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.

Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts